Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 02, 2016 16:05 ET | Source: Versartis

Versartis Presents Efficacy, Safety, Metabolic and Adherence Data for Somavaratan in Oral Session at the International Congress of Endocrinology

MENLO PARK, Calif., Sept. 02, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting...
August 22, 2016 08:30 ET | Source: Versartis

Versartis Announces Completion of Enrollment in Phase 3 VELOCITY Trial of Somavaratan in Pediatric GHD

MENLO PARK, Calif., Aug. 22, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting...
August 09, 2016 16:05 ET | Source: Versartis

Teijin Limited and Versartis Enter Strategic Alliance for Commercialization of Somavaratan Long-Acting Growth Hormone in Japan

Teijin’s regulatory and commercial infrastructure ideally suited to capitalize on somavaratan, which is positioned to be the first potential long-acting form of recombinant growth hormone (rhGH) to...
August 04, 2016 08:30 ET | Source: Versartis

Versartis to Present at the Canaccord Genuity 36th Annual Growth Conference

MENLO PARK, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting...
July 28, 2016 16:05 ET | Source: Versartis

Versartis Reports Second Quarter 2016 Financial Results

MENLO PARK, Calif., July 28, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting...
April 28, 2016 16:05 ET | Source: Aravive, Inc.

Versartis Reports First Quarter 2016 Financial Results

MENLO PARK, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting...
April 04, 2016 08:30 ET | Source: Aravive, Inc.

Versartis Presents Confirmatory Year Two Data from Ongoing Somavaratan Extension Study at Late-Breaker Session at ENDO Annual Meeting

MENLO PARK, Calif., April 04, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting...
April 01, 2016 07:00 ET | Source: Aravive, Inc.

Versartis Presents Confirmatory 18-Month Adherence Data from Ongoing Somavaratan Extension Study at Late-Breaker Session at ENDO Annual Meeting

MENLO PARK, Calif., April 01, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting...
March 30, 2016 08:30 ET | Source: Aravive, Inc.

Versartis Appoints Colin Hislop, M.D., as Chief Medical Officer

MENLO PARK, Calif., March 30, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting...
March 14, 2016 13:40 ET | Source: Aravive, Inc.

Versartis Announces Two Abstracts from Ongoing Pediatric Extension Study of Somavaratan Selected for Late-Breaker Presentations at the Endocrine Society’s 98th Annual Meeting

MENLO PARK, Calif., March 14, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting...